DealsNov 10, 2026, 08:36 AM
Ocugen Licenses OCU400 to Celairis for Up to $7.1M Plus Royalties
AI Summary
Ocugen, Inc. has entered into an exclusive license agreement with Celairis Therapeutics Holdings Pty Ltd for its investigational gene therapy, OCU400, in Australia, New Zealand, and ASEAN markets. Under the agreement, Ocugen will receive an upfront license fee, potential development and milestone payments totaling up to $7.1 million, a high-single digit percentage royalty on net sales, and 50% of gross profits. Celairis will be responsible for regional regulatory submissions and commercialization, while Ocugen retains manufacturing rights. This strategic partnership aims to expand patient access to OCU400, a potential one-time treatment for retinitis pigmentosa.
Key Highlights
- Ocugen grants Celairis exclusive license for OCU400 in Australia, New Zealand, and ASEAN markets.
- Ocugen to receive up to $7.1 million in upfront, development, and milestone payments.
- Ocugen eligible for high-single digit percentage royalty on net sales and 50% of gross profits.
- Celairis to handle regional regulatory submissions, market access, and commercialization.
- Ocugen retains sole right to manufacture OCU400 in the Territory.
- Topline data for OCU400 Phase 3 trial expected Q1 2027, with potential approval in Australia thereafter.
- License agreement continues until the later of 20-year anniversary of first commercial sale, patent expiry, or regulatory exclusivity expiry.
Price Impact
More from OCGN